YD BioMed expects to advance two lead ophthalmology programs utilizing its LSC Exosome platform, each supported by targeted regulatory and clinical milestones, which the timing of these milestones ...
Celebrating A Year of Extraordinary AchievementVancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the ...
TipRanks on MSN
BioMark leverages landmark lung cancer studies and new funding to drive 2026 expansion
BioMark Diagnostics ( ($TSE:BUX) ) has issued an announcement. BioMark Diagnostics reported a transformative 2025 marked by major capacity ...
The firm will retrospectively analyze data from more than 1,100 breast cancer patients treated in Unicancer's clinical trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback